Breakeven Date Change • Jun 30
Forecast breakeven date moved forward to 2026 The analyst covering Navamedic previously expected the company to break even in 2028. New forecast suggests the company will make a profit of kr1.00m in 2026. Earnings growth of 106% is required to achieve expected profit on schedule. Announcement • Jun 16
Navamedic ASA Announces CEO Changes Navamedic ASA announced that Kathrine Gamborg Andreassen stepped down from her position as Chief Executive Officer (CEO), effective June 16, 2026, to pursue opportunities outside the company. Gamborg Andreassen served as CEO since 2019 and played a key role in developing Navamedic into a leading Nordic specialty pharmaceutical company. During her tenure, Navamedic grew its revenues from NOK 189 million in 2019 to NOK 565 million in 2025 through organic growth, acquisitions, and expansion into new therapeutic areas. The Board of Directors appointed Lars Minor as Navamedic’s new Chief Executive Officer, effective from June 18, 2026. Minor most recently served as the Chief Executive Officer of Newbury Pharmaceuticals where he led the company’s transition from an early-stage platform company to a commercially business, leading up to a successful IPO on Nasdaq First North. Prior to Newbury Pharmaceuticals, Lars held several senior leadership positions at LEO Pharma, including Corporate Vice President, Strategy Execution and Change, and Vice President, Region EUROPE+. In these roles, Minor was responsible for shaping and executing the company’s global strategy and leading business transformation initiatives across the organization. Kathrine Gamborg Andreassen will support the company during a brief transition period to ensure continuity of operations. Announcement • May 23
Navamedic Asa Launches Virono The First Single Dose Over The Counter Cold Sore Tablet Navamedic ASA announced the launch of Virono®, the first over-the-counter single-dose treatment for recurrent cold sores (herpes labialis) in adults. The launch establishes a new OTC treatment category and represents an important step in Navamedic's Nordic Consumer Health growth strategy. Virono is available in Swedish pharmacies from May 2026. Roll-out activities have also been initiated in Finland, while launch in the Netherlands is planned later in 2026. A new way to treat cold sores: one tablet per outbreak, applied once at the first sign of symptoms. Rx-to-OTC switch brings antiviral treatment into self-care for the first time in this format. Patented Lauriad® mucoadhesive buccal technology delivers aciclovir locally and continuously from a single tablet. Approximately 80% of Swedish adults carry herpes simplex virus type 1 (HSV-1), and approximately 1 million Swedes experience at least three outbreaks annually. OTC cold sore market size value approximately NOK 70 million wholesaler value in Sweden, Finland, The Netherlands. Virono® is a prescription-free medicine containing 50 mg aciclovir in a mucoadhesive buccal tablet designed for local treatment of recurrent cold sores. The tablet is applied once per outbreak at the first signs of symptoms. Providing an alternative to topical OTC treatments (creams, sticks, patches) that require repeated daily applications. The launch supports Navamedic's strategy to expand its Consumer Health portfolio through differentiated self-care and OTC products across the Nordics and selected European markets. Virono® (aciclovir 50 mg mucoadhesive buccal tablet) is an OTC medicine for treatment of recurrent herpes labialis (cold sores) in adults with normal immune function. Virono® is applied once per outbreak (single-dose) at the first signs or symptoms. Board Change • May 20
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Rune Wahl is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Announcement • Jan 07
Navamedic ASA Approves Board Appointments Navamedic ASA at the extraordinary general meeting held on 7 January 2026, the following board members are elected for a term until the annual general meeting in 2026: Morten Jurs (chair); Mods Helmich Pedersen (board member). Board Change • Dec 30
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Edmee Steenken was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Nov 28
Navamedic ASA Announces CFO Changes Navamedic ASA announced that the Company and its Chief Financial Officer (CFO), Lars Hjarrand, on November 28, 2025 has entered into an agreement whereby Hjarrand will step down as CFO of the Company to pursue new opportunities outside the Company. Director of Group Accounting, Pål Zimmermann Vonen will assume the role as acting CFO until a new permanent CFO has been appointed. Announcement • Oct 07
Navamedic ASA has completed a Follow-on Equity Offering in the amount of NOK 129.999987 million. Navamedic ASA has completed a Follow-on Equity Offering in the amount of NOK 129.999987 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,046,511
Price\Range: NOK 21.5
Discount Per Security: NOK 1.075
Transaction Features: Regulation S; Rights Offering Announcement • Aug 13
Navamedic ASA Receives Final Approval for the Packaging Material in National Language for Norway, Sweden and Denmark Navamedic announced that it has received final approval for the packaging material in national languages for Norway, Sweden and Denmark, following the earlier announcement on June 27th. Orion Corporation has also obtained final confirmation for the Finnish market. Flexilev in OraFID ensures precise and personalized treatment tailored to individual Parkinson's Patient needs. Medications with a narrow therapeutic window can benefit from hyper-fractionation, which involves administering smaller, more frequent doses. OraFID is a unique, patented, fully mechanical medical device that dispenses precise quantities of minitablets with just a few of twists of the hands. The launch in the Nordic markets is still anticipated in October 2025. Announcement • Jun 29
Navamedic Asa Announces First Approval of the Medical Device Orafid as Primary Package for A Pharmaceutical Product Navamedic announced that the Swedish Medical Products Agency, acting as the Reference Member State, together with the Concerned Member States in 9 additional countries have approved OraFID for use with a medicinal product. Treatments with a narrow therapeutic window can benefit from hyper-fractioning of the dose, by dividing it into minitablets, each containing a fraction of the dose. OraFID works with a couple of twists of the hands and ejects an exact number of minitablets. It is approved as an integral combination product for Flexilev, Navamedic's medication for the treatment of Parkinson's. The launch in Nordic markets is anticipated in October 2025. Announcement • Jun 24
Navamedic ASA has filed a Follow-on Equity Offering in the amount of SEK 129.999987 million. Navamedic ASA has filed a Follow-on Equity Offering in the amount of SEK 129.999987 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,046,511
Price\Range: SEK 21.5
Discount Per Security: SEK 1.075
Transaction Features: Regulation S; Rights Offering Announcement • Jun 05
Navamedic ASA Approves Board and Committee Elections Navamedic ASA announced that at its AGM held on 4 June 2025, the shareholders approved election of Morten Juurs as board of director for a one-year term, until the annual general meeting in 2026. Bard Brath Ingero (chair), Katarina Hammar and Kristian Huseby are elected as members of the nomination committee for a one-year term, until the annual general meeting in 2026. Recent Insider Transactions • Nov 14
Chief Financial Officer recently bought €40k worth of stock On the 6th of November, Lars Hjarrand bought around 20k shares on-market at roughly €2.00 per share. This transaction amounted to 6.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth €131k. This was Lars' only on-market trade for the last 12 months. Announcement • Nov 07
Navamedic Launches Eroxon in Finland Building on the successful product launch of Eroxon® in Norway and Sweden earlier this year, Navamedic ASA is now launching Eroxon® across pharmacies in Finland. Eroxon® will be the first clinically proven over-the-counter topical treatment for the treatment of erectile dysfunction in men in Finland. Eroxon® is part of Navamedic's increasingly growing Consumer Health category. Since the product launched in Norway in February 2024, Eroxon® has already become one of the top performing products within this category, and it is expected to continue driving further growth. The product launch in Finland marks the third launch this year and will be followed by a launch in Denmark in 2025. The Finnish market for erectile dysfunction has significant potential. A recent study concluded that 37% of Finnish men above 18 years of age, more than 800,000 men, have had first-hand experience with erectile dysfunction. Two in three of these men had previously sought help to medically treat the condition, indicating that men in Finland have a higher willingness to treat the condition than their neighbours in other Nordic countries. Eroxon® offers a range of features which differentiates it from other forms of treatments for erectile dysfunction. It is an effective and fast-acting gel which typically helps men get an erection within ten minutes of application. It has a good safety profile due to its local effect with no systemic absorption. Eroxon® is approved as a treatment for erectile dysfunction in the EU and the US. New Risk • Nov 06
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.7% Last year net profit margin: 6.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.7% net profit margin). Market cap is less than US$100m (€36.0m market cap, or US$38.6m). Reported Earnings • Nov 01
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: kr123.1m (down 13% from 3Q 2023). Net income: kr2.74m (down 60% from 3Q 2023). Profit margin: 2.2% (down from 4.8% in 3Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Valuation Update With 7 Day Price Move • Nov 01
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €2.10, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 19% over the past three years. Recent Insider Transactions • Aug 22
Director recently bought €131k worth of stock On the 20th of August, Rune Wahl bought around 50k shares on-market at roughly €2.62 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €125k more in shares than they have sold in the last 12 months. Reported Earnings • Aug 17
Second quarter 2024 earnings released: EPS: kr1.17 (vs kr0.92 loss in 2Q 2023) Second quarter 2024 results: EPS: kr1.17 (up from kr0.92 loss in 2Q 2023). Revenue: kr156.3m (up 26% from 2Q 2023). Net income: kr20.3m (up kr36.1m from 2Q 2023). Profit margin: 13% (up from net loss in 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Reported Earnings • May 02
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr120.9m (flat on 1Q 2023). Net loss: kr1.58m (down 112% from profit in 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Announcement • Mar 13
An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million. An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million on March 12, 2024. As part of acquisition, 2,965,618 shares were acquired for NOK 32 per share.An unknown buyer completed the acquisition of unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million on March 12, 2024. New Risk • Feb 17
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 60% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (1.5% operating cash flow to total debt). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.7% net profit margin). Market cap is less than US$100m (€58.1m market cap, or US$62.6m). Reported Earnings • Feb 16
Full year 2023 earnings released Full year 2023 results: Revenue: kr512.0m (up 34% from FY 2022). Net income: kr3.81m (down 87% from FY 2022). Profit margin: 0.7% (down from 7.7% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Reported Earnings • Nov 06
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr141.0m (up 52% from 3Q 2022). Net income: kr6.77m (up 154% from 3Q 2022). Profit margin: 4.8% (up from 2.9% in 3Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Valuation Update With 7 Day Price Move • Sep 14
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €3.14, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 19x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 78% over the past three years. New Risk • Aug 15
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 44% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (44% net debt to equity). Large one-off items impacting financial results. Market cap is less than US$100m (€49.3m market cap, or US$53.8m). Reported Earnings • Aug 15
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr124.0m (up 12% from 2Q 2022). Net loss: kr15.8m (down 316% from profit in 2Q 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 143% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 14
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €2.86, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 22x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 44% over the past three years. Announcement • Jun 02
Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors Navamedic ASA at its annual general meeting held on June 1, 2023, elected Åsa Kornfeld as members of the Company's board of directors for a one-year term, until the annual general meeting in 2024. Reported Earnings • May 12
First quarter 2023 earnings released First quarter 2023 results: EPS: kr0.77. Revenue: kr121.8m (up 93% from 1Q 2022). Net income: kr13.2m (up kr13.9m from 1Q 2022). Profit margin: 11% (up from net loss in 1Q 2022). Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 128% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 17
Full year 2022 earnings released Full year 2022 results: Revenue: kr382.1m (up 37% from FY 2021). Net income: kr29.4m (up kr28.8m from FY 2021). Profit margin: 7.7% (up from 0.2% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Announcement • Jan 31
Navamedic ASA Launches Modifast in Norway Navamedic ASA announced it has launched Modifast, a range of low calorie diet (LCD) meal replacement products, in the Norwegian market. Modifast is part of Navamedic's growing portfolio of products and solutions aimed at tackling obesity and consists of supplements, prescription medications, diet replacements and online patient support portals. Obesity is an increasingly growing public health challenge, and according to the World Health Organization (WHO), obesity has nearly tripled since 1975. Between 15% and 20% of people in the Nordic population are considered obese, and as a consequence, the cost of treatment and related complications are increasing. Weight loss through lifestyle intervention remains a key treatment option in the management of obesity and is often a prerequisite for patients seeking to undergo bariatric surgery. Low calorie diets are full diet replacement products, providing 800-1200 calories per day if all regular food is replaced. Modifast is considered a low calorie diet (LCD) and is made up of drinks, soups, puddings and pasta dishes, which have all been developed to contain necessary nutrients. Modifast is product range consisting of Low Calorie Diet (LCD) meal replacement products. It is designed to replace all other foods for a limited time period during weight loss or weight control, without depriving the body of the nutrients it needs. Modifast cost substitute contains between 800 and 1200 kcal per day. Modifast has a wide range of products for weight loss, weight control and well -being. Modifast has been on the market in Europe since 1995 and is recommended by obesity clinics. How Modifast can help user depends on what customer weight goalis. Different products and approaches work well in different situations. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Edmee Steenken was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 02
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr92.8m (up 46% from 3Q 2021). Net income: kr2.67m (up kr4.59m from 3Q 2021). Profit margin: 2.9% (up from net loss in 3Q 2021). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Pharmaceuticals industry in Germany. Announcement • Oct 20
Navamedic ASA Launches Forlaxgo® Navamedic ASA announced the launch of ForlaxGO® across pharmacies in Norway, Sweden, Finland and Denmark. ForlaxGO® is a unique product that relieves the symptoms of occasional constipation in adults and children above 8 years of age. The launch is part of a long-term agreement with Ipsen Consumer HealthCare, a reputable French pharmaceutical company, whereby Navamedic is the exclusive partner in the Nordics. ForlaxGO® is an on-the-go, ready-to-drink suspension that relieves the symptoms of occasional constipation in adults and children above 8 years of age. The main component of the product is macrogol, which provides a sense of natural relief. ForlaxGO® is presented as a ready-to-use solution in a single-dose sachet and can be bought at pharmacies without a prescription. Constipation is defined as slow, hard or infrequent stools. The problem is widespread among older people and is three times as common among women as men. 20% of the population experience or live with constipation, and about 10 percent use laxatives. Announcement • Jun 02
Navamedic ASA (OB:NAVA) acquired Impolin AB for SEK 55 million . Navamedic ASA (OB:NAVA) agreed to acquire Impolin AB for SEK 55 million on May 5, 2022. Under the terms, Navamedic ASA will issue shares worth SEK 25 million and the remaining amount will be paid in cash. Also, an additional consideration in the amount of SEK 5 million will be paid if certain pre-agreed milestones for Impolin AB are satisfied by year-end 2022. Impolin team will work together with the team at Navamedic. The completion of the transaction is subject to Impolin AB amending one of its material agreements on terms and conditions satisfactory to Navamedic, in addition to certain customary conditions. It is expected that the transaction will be completed during Q2 2022.
Navamedic ASA (OB:NAVA) completed the acquisition of Impolin AB on June 1, 2022. Reported Earnings • May 11
First quarter 2022 earnings released First quarter 2022 results: Revenue: kr63.0m (up 7.4% from 1Q 2021). Net loss: kr710.0k (loss narrowed 81% from 1Q 2021). Over the next year, revenue is forecast to grow 30%, compared to a 6.1% growth forecast for the industry in Germany. Announcement • May 06
Navamedic ASA (OB:NAVA) agreed to acquire Impolin AB. Navamedic ASA (OB:NAVA) agreed to acquire Impolin AB for SEK 55 million on May 5, 2022. Under the terms, Navamedic ASA will issue shares worth SEK 25 million and the remaining amount will be paid in cash. Also, an additional consideration in the amount of SEK 5 million will be paid if certain pre-agreed milestones for Impolin AB are satisfied by year-end 2022. Impolin team will work together with the team at Navamedic. The completion of the transaction is subject to Impolin AB amending one of its material agreements on terms and conditions satisfactory to Navamedic, in addition to certain customary conditions. It is expected that the transaction will be completed during Q2 2022. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Annika Kollen was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 18
Full year 2021 earnings: Revenues exceed analyst expectations Full year 2021 results: Revenue: kr278.4m (up 33% from FY 2020). Net income: kr618.0k (up kr17.1m from FY 2020). Profit margin: 0.2% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Over the next year, revenue is forecast to grow 17%, compared to a 7.6% growth forecast for the pharmaceuticals industry in Germany. Announcement • Feb 17
Navamedic ASA launches SmectaGO - an innovative on-the-go product for treatment of diarrhea Navamedic ASA announces the launch of SmectaGO® for sale through pharmacies in Norway, Sweden, Finland and Denmark this spring. SmectaGO® is a unique product developed to treat acute and chronic diarrhea in adults and children above 8 years. The launch is part of a long-term agreement with the well known French pharmaceutical corporation Ipsen Consumer HealthCare wherein Navamedic has been appointed the exclusive partner in the Nordics. SmectaGo® is a ready-to-drink suspension for use in the treatment of acute diarrhea in adults and children above 8 years of age. The main component of the product is diosmectite, a natural clay that helps in the inhibition and treatment of diarrhea and in relieving abdominal pain. The agreement with Ipsen Consumer HealthCare will strengthen Navamedic's position in the gastroenterology category, which represents a significant growth potential in the Consumer Health segment where patients can find approved treatment options without prescriptions in the pharmacies. As part of the agreement, Navamedic will also take over the distribution and sales in Sweden of Forlax®, a prescription drug for the treatment of constipation in adults and children aged 8 years and above. Announcement • Dec 24
Navamedic Asa Provides Revenue Guidance for the Full Year 2021 and 2022 Navamedic ASA updated updated revenue growth expectation for the full-year 2021 of around 30%. Going into 2022, Navamedic maintains its annual growth target of 20%. Reported Earnings • Nov 05
Third quarter 2021 earnings released The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: kr63.6m (up 12% from 3Q 2020). Net loss: kr1.92m (loss widened kr1.69m from 3Q 2020). Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS kr0.20 (vs kr0.037 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr66.0m (up 57% from 2Q 2020). Net income: kr3.19m (up kr2.68m from 2Q 2020). Profit margin: 4.8% (up from 1.2% in 2Q 2020). The increase in margin was driven by higher revenue. Announcement • Jun 02
Navamedic ASA Announces the Launch of New Products in the Nordics Navamedic ASA (Navamedic) announced the launch of new products in the Nordics. Medical Nutrition is a strategically important area for Navamedic and to further strengthen presence, the company has now launched three new products in this category. The first to be launched is Glycosade Lemon for the dietary treatment of Glycogen Storage Disease (GSD), an inborn error of metabolism. The other two, K.Flo and K.Yo, are both used for the dietary management of drug-resistant epilepsy or other conditions for which a ketogenic diet is indicated. Navamedic has products that combine the best of cutting-edge research with the lifestyle demands of modern living. By launching new products to meet complex dietary treatments, Navamedic will continue to offer new product lines throughout the year, always with the patient at the core. The Medical Nutrition business segment is based on the sale of products for the treatment of inborn errors of metabolism (IEM). Within Medical Nutrition, Navamedic is a Nordic distributor of products purchased from the UK based company Vitaflo International ltd, a subsidiary of Nestlé. Navamedic's vendor Vitaflo has more than 30 years of experience in producing specialist nutritional products for Inborn Errors of Metabolism (IEM). Announcement • May 21
Navamedic Launches Mycontrol Support in Norway, A Free-Of-Charge Patient Support Program in Collaboration with Observia, Following A Successful Launch in Sweden Navamedic launched MyControl Support in Norway, a free-of-charge patient support program in collaboration with Observia, following a successful launch in Sweden. A new patient engagement & support program targeted towards people with clinical obesity. Via a brand-new online platform, the program aims to aid and inform patients with obesity. Navamedic, a Nordic pharma company, specialized in the field of obesity and Observia, French e-health company specialized in patient engagement and support solutions are proud to further provide support for patients in great need. Patients embark on a 16-week program, comprising lifestyle recommendations and doctor- and patient-validated information via SMS. Participants also receive articles on topics such as the causes, risks and benefits of long-term weight loss as well as treatment option information. In addition, patients are invited to take on daily challenges (going to bed early, practicing physical activity, eating healthy) that instil healthy habits and to progress across 10 levels of challenge. Any patient suffering from obesity can enrol in the program. The design and the interface of the platform have been conceived by Navamedic and Observia to encourage patients every day and engage them to play an active role in the management of their health. The patient support program was first launched in Sweden in October 2020. After first promising results, the decision was taken to further deploy the program in Norway, where 23.1% of the population suffers from obesity. Obesity is linked to increased incidence of many chronic diseases (type 2 diabetes, CVD, respiratory complications, etc.) which lead to increased morbidity. In the past few decades, greater awareness around obesity and its consequences and burden have fostered the creation of dedicated support actions and prevention. Reported Earnings • May 12
First quarter 2021 earnings released The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: kr58.6m (up 5.4% from 1Q 2020). Net loss: kr3.67m (loss narrowed 69% from 1Q 2020). Is New 90 Day High Low • Mar 02
New 90-day high: €2.73 The company is up 53% from its price of €1.78 on 02 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period. Reported Earnings • Feb 20
Full year 2020 earnings released The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: kr209.9m (up 11% from FY 2019). Net loss: kr16.5m (loss widened 1.0% from FY 2019). Is New 90 Day High Low • Feb 10
New 90-day high: €2.09 The company is up 6.0% from its price of €1.97 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. Is New 90 Day High Low • Oct 29
New 90-day low: €1.59 The company is down 11% from its price of €1.79 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. Is New 90 Day High Low • Sep 22
New 90-day low: €1.68 The company is down 9.0% from its price of €1.85 on 24 June 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period. 
